Companies · Pharmaceuticals

Novellus LLC

CAMBRIDGE · Pharmaceuticals

Diligence memoA one-page analyst read on Novellus LLC — recommendation, valuation, rhythm, risks.
$3.0M
Total raised · real
3
Rounds
1.0×
Latest step-up
Top 67%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Mar 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Novellus LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.50× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.3 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Novellus LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.7 yr record
Peak capital year was 2016 with $1.0M across 1 filings.
Market position
ahead of 34% of Pharmaceuticals peers
Capital scale is ahead of 34% of Pharmaceuticals peers; modeled value is above 42% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2016: $1.0M across 1 filings.
  • Largest single filing was $1.0M on 2016-10-11.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Novellus LLC is one of 1610 Pharmaceuticals companies tracked from CAMBRIDGE. By capital raised it ranks in the long tail (ahead of 34% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2014
Year incorporated
2018-03-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2016-10-11 Raised $1.0M (real) Modeled valuation $47M (est)$1.0M$47MPre-Seed2016Pre-Seed · 2017-02-03 Raised $1.0M (real) Modeled valuation $47M (est)$1.0M$47MPre-Seed2017Pre-Seed · 2018-03-01 Raised $1.0M (real) Modeled valuation $47M (est)$1.0M$47MPre-Seed2018+$1.0M+$1.0MCumulative $3.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2016
Pre-Seed extension$1.0M · 2017
Pre-Seed extension$1.0M · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$47.3M
Base estimate est.
$560K
Conservative case
$536.3M
Upside case
$5.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $47.3M · 2016-10-112016Pre-Seed · modeled $47.3M · 2017-02-03Pre-Seed · modeled $47.3M · 2018-03-012018
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
8.3 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$2.2M/yr
Capital velocity
9.7 yr
On record since
2016
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$3.0M
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 2.4× above median
This company$1.0M
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$47.3M
Sector median$76.1M

Raised more than 34% of sector peers (real $). Modeled value above 42% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 56.

This companyCohort peer
$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Blake Insomnia Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Socal, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Essentia Pharma Florida, Llc · Pre-Seed Raised $1.0M · modeled $47.3M (est)Eleusis Benefit Corporation, PBC · Pre-Seed Raised $1.7M · modeled $46.2M (est)Blc Usa Lp · Pre-Seed Raised $813K · modeled $38.5M (est)T.A.Z. Corp · Pre-Seed Raised $813K · modeled $38.5M (est)ReveraGen BioPharma, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)Cyto-Sen Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $37.8M (est)WinSanTor · Pre-Seed Raised $783K · modeled $37.0M (est)Pelagius Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Apothecary Health Solutions, LLC · Pre-Seed Raised $725K · modeled $34.3M (est)Novellus LLC (this company) Raised $3.0M · modeled $47.3M (est)Novellus LLC
CompanyStageRaised · realValue · estvs peer med.
Novellus LLC this companyPre-Seed$3.0M$47.3M2.50×
Blake Insomnia Therapeutics, Inc.Pre-Seed$1.0M$47.3M2.50×
Essentia Pharma Socal, LlcPre-Seed$1.0M$47.3M2.50×
Essentia Pharma Florida, LlcPre-Seed$1.0M$47.3M2.50×
Eleusis Benefit Corporation, PBCPre-Seed$1.7M$46.2M2.44×
Blc Usa LpPre-Seed$813K$38.5M2.03×
T.A.Z. CorpPre-Seed$813K$38.5M2.03×
ReveraGen BioPharma, Inc.Pre-Seed$800K$37.8M2.00×
Cyto-Sen Therapeutics, Inc.Pre-Seed$800K$37.8M2.00×
WinSanTorPre-Seed$783K$37.0M1.96×
Pelagius Inc.Pre-Seed$750K$35.5M1.87×
Apothecary Health Solutions, LLCPre-Seed$725K$34.3M1.81×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2016-10-11$5.6M$47.3M90%
Pre-Seed$1.0M2017-02-03$5.6M$47.3M90%
Pre-Seed$1.0M2018-03-01$5.6M$47.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2016-10-11
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$1.0M2017-02-03
    • Came back fast: 4 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  3. Pre-Seed$1.0M2018-03-01
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2018 ~Q4
Modeled next raise · ~8mo cadence
$1.0M
Modeled next size est.range $1.0M$1.6M
1.0×
Last step-up
$2.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Matthew Angel4 other2016-10
Christopher Rohde2 other2016-10
Registry & provenance

Novellus LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1687472
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Novellus, Inc.PharmaceuticalsPre-Seed$250K$11.8Mnetwork2 shared operators · same sector · same stage
Stocosil Inc.PharmaceuticalsPre-Seed$3.0M$26.8Msame sector · same stage
Factor Bioscience LLCBiotechnologyPre-Seed$1.0M$2.2Mnetwork2 shared operators · same stage
Elite Pharmaceuticals Inc /Nv/PharmaceuticalsPre-Seed$3.3M$23.4Msame sector · same stage
Exodos Life Sciences Limited PartnershipPharmaceuticalsPre-Seed$2.7M$32.6Msame sector · same stage
VR1 CorpPharmaceuticalsPre-Seed$2.5M$42.6Msame sector · same stage
Flex Biomedical, Inc.PharmaceuticalsPre-Seed$2.4M$41.7Msame sector · same stage
Terpenoid Therapeutics, Inc.PharmaceuticalsPre-Seed$2.3M$25.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Novellus Holdings, Inc.Other TechnologySeries A$20.3M80%
Avant Sciences, Inc.PharmaceuticalsPre-Seed$1.0M78%
NLS Pharmaceutics Ltd.PharmaceuticalsSeries A$3.3M78%
Marius Pharmaceuticals, LLCPharmaceuticalsSeries B$129.3M78%
TIXiMED, Inc.PharmaceuticalsPre-Seed$2.1M78%
Kp Biosciences, Inc.PharmaceuticalsPre-Seed$13.2M78%
Pharmapotheca A, LLCPharmaceuticalsSeed$87.1M78%
Concordia International Corp.PharmaceuticalsSeries D+$8.1B78%
Frequently asked
How much funding has Novellus LLC raised?
Novellus LLC has raised approximately $3.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Novellus LLC's estimated valuation?
Provath's modeled valuation for Novellus LLC is approximately $47.3M (modeled range $560K–$536.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Novellus LLC at?
Novellus LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Mar 01.
What does Novellus LLC do and where is it based?
Novellus LLC operates in the Pharmaceuticals sector, based in CAMBRIDGE.
Explore related

See where Novellus LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Novellus LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.